Arcturus Therapeutics vs Eton Pharmaceuticals
Arcturus Therapeutics reported revenue of $82 million in fiscal 2025, about the same as Eton Pharmaceuticals' $80 million in fiscal 2025. Arcturus Therapeutics' revenue fell 46.1% in its latest year, and Eton Pharmaceuticals' grew 104.9%. Arcturus Therapeutics had an operating margin of -93.0%, against -1.1% at Eton Pharmaceuticals. Free cash flow was −$74 million at Arcturus Therapeutics and $10 million at Eton Pharmaceuticals.
Side by side
| Arcturus Therapeutics | Eton Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $82M | $80M |
| Revenue growth | −46.1% | 104.9% |
| Revenue growth a year, last 5 years | 53.9% | — |
| Gross margin | — | 53.5% |
| Operating margin | −93.0% | −1.1% |
| Net margin | −80.2% | −5.8% |
| Free cash flow | −$74M | $10M |
| Free cash flow margin | −90.8% | 12.8% |
| Return on capital | — | −1.9% |
| Net debt to EBITDA | — | 1.4x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.4% | 3.9% |
| Last close | $7.60 | $61.36 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $25.2 million |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arcturus TherapeuticsEton Pharmaceuticals
Operating margin
Percent of revenue
Arcturus TherapeuticsEton Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcturus TherapeuticsEton Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcturus Therapeutics and Eton Pharmaceuticals pages.